An open label study to evaluate the effect of PEGASYS [peginterferon alfa-2a] on ALT [alanine transminase] and HBV [hepatitis-B virus] DNA levels in patients with lamivudine-resistant HbeAg-negative chronic hepatitis B.

Trial Profile

An open label study to evaluate the effect of PEGASYS [peginterferon alfa-2a] on ALT [alanine transminase] and HBV [hepatitis-B virus] DNA levels in patients with lamivudine-resistant HbeAg-negative chronic hepatitis B.

Discontinued
Phase of Trial: Phase IV

Latest Information Update: 02 Jun 2010

At a glance

  • Drugs Peginterferon alfa-2a (Primary)
  • Indications Hepatitis B
  • Focus Therapeutic Use
  • Sponsors Roche
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 30 Jun 2008 Status changed from recruiting to discontinued, as reported by Roche.
    • 22 Oct 2007 Status changed from initiated to recruiting
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top